RollingStone롤링스톤

RollingStone remains loss-making, with the share price down about 45% over the past year and a sharp 2026 revenue rise that has not closed the gap to losses.

RollingStone sells molecular diagnostic instruments and kits and has a petroleum wholesale business. On trailing twelve-month figures to H1 2026 it reported ₩70.6B of revenue, an operating loss of ₩9.7B and a net loss of ₩21.6B, with free cash flow of about -₩9.6B. At ₩2,290 the market value is about ₩19.2B, and the data shows no investor flow, short-selling or analyst coverage figures.

What stands out

• Trailing revenue of ₩70.6B is far above the ₩10.9B reported for 2025, but the trailing operating margin is still -13.7% and the net margin is -30.6%.
• Annual revenue fell from ₩30.3B in 2021 to ₩4.4B in 2024 before recovering to ₩10.9B in 2025, so the top line has been volatile.
• Losses have been large relative to size in every year shown, and return on equity is deeply negative at -116.2%.
• Cash of about ₩2.4B is small against the reported free cash outflow, and the liabilities-to-equity ratio is 42.8%; the data shows no borrowings figure.
• The share price is down 44.9% over one year, trading near ₩2,290 against a 52-week high of ₩4,705 and a low shown as ₩0; the dividend yield is 0%.

What to watch

• The full-year 2026 results and the next quarterly report, to see whether the revenue gain turns into operating profit.
• The auditor's adverse opinion on the half-year review and the capital impairment disclosure, which the filings flag as a serious issue for the company's equity.
• The outcome of the loan period extension and any further shareholder meeting decisions listed in recent filings.